医学
新辅助治疗
化疗
内科学
阶段(地层学)
回顾性队列研究
肿瘤科
胃肠病学
外科肿瘤学
癌症
外科
乳腺癌
生物
古生物学
作者
James W. Jakub,Wenxia Zhang,Malvika Solanki,Jennifer Yonkus,Judy C Boughey,Scott Harmsen,Karthik V Giridhar
标识
DOI:10.1177/00031348221135778
摘要
A gap remains in the role of neoadjuvant therapy for patients with ILC.Single-institution retrospective review of patients with ILC who received neoadjuvant therapy between 2008 and 2019.141 patients met inclusion criteria: 71 neoadjuvant chemotherapy (NACT) and 70 neoadjuvant endocrine therapy (NET). 7/71 (9.9%) patients had a pCR following NACT compared to 1/70 (1.4%) with NET (P = .063). pCR was observed in 5/18 (27.8%) patients with Her2Neu-positive disease following NACT, compared to 2/53 (3.8%) with Her2Neu-negative disease (P = .01).For luminal B tumors, median Ki-67 decrease was similar following NACT and NET (18.3 vs 16.3, P = .26).T category decreased in 59 (42.1%) patients following neoadjuvant therapy, increased in 9 (6.4%), and was unchanged in 72 (51.4%). More patients had an increase (28.6%) than decrease (12.1%) in their N category, including 13/60 (21.7%) who were clinically node-negative at diagnosis and identified to have node-positive disease following neoadjuvant therapy, at definitive surgery.In Her2Neu-negative ILC, the potential of a pCR with NACT or NET is low. Most patients' nodal status and tumor size remain unchanged. There is a potential for pathologic stage to be higher at surgery compared to the clinical stage prior to neoadjuvant therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI